COVID-19

This study covers 21 industrialized countries and the time from mid-February to the End of May 2020. The study estimates that 206,000 (95% credible interval, 178,100–231,000) more people died in these countries than would have had the pandemic not occurred but this includes the taken measures. England and Wales and Spain experienced the largest impact with a 37% (30–44%) relative increase of all-cause mortality in England and Wales and 38% (31–45%) in Spain.

This comprehensive review article provides system-by-system review of COVID-19 disease. Part 2 focuses on radiologic findings of the heart, brain, abdomen, skin, and musculoskeletal system and reviews the specific manifestations of the disease in children and pregnant women.

This comprehensive review article provides system-by-system review of COVID-19 disease. Part 1 focuses on viral pathophysiology, clinical findings and imaging findings of the respiratory and vascular system

Post-mortem CT may contribute to the diagnosis of COVID-19 pneumonia and guide autopsy practice in cases of unsuspected COVD-19 infection.

Kommentar einer Anthropologin, in welchem sie die Hypothese aufstellt, dass insbesondere von der eigenen Besonderheit überzeugte Nationen schlecht durch die Pandemie kommen. Illustriert mit zahlreichen Beispielen und Gegenbeispielen.

Ein Online-Symptom-Checker, der basierend auf den aktuellen Guidelines des BAG eine Empfehlung abgibt, ob ein Kind einen Coronatest benötigt oder weiter in die Kita oder Schule gehen kann.

Eine sehr gute Zusammenfassung der 4 soeben erschienenen, randomisierten Studien zum Effekt von Toclizumab (Actemra) bei Patienten mit COVID-19, sowie eine Gegenüberstellung zu der grossen Beobachtungsstudie, die einen ersten Mortalitätsbenefit nahegelegt hatte. In den Worten des Autors: "Newly released randomized trials [...] do not show clear evidence of efficacy, in contrast to observational studies. Their findings do not support the routine use of tocilizumab for COVID-19 in most settings."

In silico structure based computational analysis demonstrates that the SARS-CoV-2 spike (S) glycoprotein exhibits a high-affinity motive for binding T-cell receptors and may form a complex with MHCII. The binding epitope is unique to SARS-CoV-2, not present on other coronaviruses and is highly similar to the bacterial superantigen staphylococcal enterotoxin B.

A study from 405 hospitals in 30 countries included 11'266 patients and tested Remdesivir, Lopinavir, Hydroxychloroquine and Interferon with an intent-to-treat primary analyses of in-hospital mortality in the 4 pairwise comparisons of each study drug vs its controls. These regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality. The findings are consistent with meta-analyses of mortality in all major trials.

A prospective study including 71 patients in University Hospital Bern between March 20 and April 26, 2020. 25 patients were allocated for expedited AVR, 46 for deferred AVR. Hospitalizations for valve-related symptoms or worsening heart failure were more common in patients allocated to deferred AVR. The group who required hospitalization for valve-related symptoms or worsening heart failure more commonly had multivalvular disease.